FDA provides Feedback in Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors October 28, 2026
FDA grants traditional approval for Keytruda or Keytruda Qlex for unresectable or metastatic TMB-H solid tumors with updated indication October 27, 2026
Vir Biotechnology and Gilead Sciences to Discover and Develop Novel PRO-XTEN® Dual-masked T-cell Engagers for Solid Tumors October 20, 2026
Hansoh Pharma Announces Strategic Collaboration and License Agreement With Roche to Advance Novel ADC Portfolio October 20, 2026
Alentis and PinotBio announce collaboration to develop next-generation ADCs targeting claudin-1 October 20, 2026
Adlai Nortye Enters Clinical Collaboration with Lilly and Merck KGaA to Evaluate Combination of AN4035 and Cetuximab October 20, 2026
FDA grants Fast-Tracks designation to Invikafusp Alfa for Previously Treated TMB-High Solid Tumors October 20, 2026
Type B meeting provided clear guidance for next steps to prepare IND application for HCW11-018b in solid tumors October 14, 2026
AstraZeneca, Daiichi Sankyo, and Summit Therapeutics to evaluate Datroway + ivonescimab combo across multiple tumour types October 6, 2026
United Immunity Announces Master Clinical Supply Agreement with Roche to Evaluate UI-102 + Anti–PD-L1 Therapy in Advanced Solid Tumors October 6, 2026
Abogen Announces Licensing and Option Agreement with Novartis to Advance mRNA-Encoded T-Cell Engager and other potential RNA programs October 6, 2026
FDA IND clearance for Ph 1 trial of CUR-001 in mesothelin-positive advanced refractory solid tumours October 6, 2026
Henlius and Amberstone Partner to Develop Next-Generation Conditionally Activated TCEs for Solid Tumours October 1, 2026
